Estramustine binding protein in human brain-tumor tissue

1991 ◽  
Vol 74 (6) ◽  
pp. 962-964 ◽  
Author(s):  
Eva von Schoultz ◽  
Tommy Bergenheim ◽  
Kjell Grankvist ◽  
Roger Henriksson

✓ Estramustine, an estradiol-17β and nornitrogen mustard complex, is used in the treatment of advanced prostatic carcinoma. A specific estramustine binding protein (EMBP) is important for its cytotoxic action, and the presence of EMBP has previously been demonstrated in rat and human prostatic cancer tissue. Significant levels of EMBP were detected by radioimmunoassay in human brain-tumor tissue. The EMBP concentrations (expressed as ng/mg protein) in 16 astrocytomas (mean 2.6 ng/mg, range 0.5 to 6.2 ng/mg) and seven meningiomas (mean 5.1 ng/mg, range 0.3 to 9.3 ng/mg) were significantly higher than that found in four samples of epileptic brain (mean 0.7 ng/mg, range 0.5 to 1 ng/mg) and 18 samples of normal brain (mean 0.5 ng/mg, range 0.2 to 1.0 ng/mg). The uptake, metabolism, and antiproliferative effects of the prostatic anticancer agent estramustine have been previously demonstrated in cultured glioma cells. The presence of EMBP may suggest a selective binding and effectiveness in human brain-tumor tissue.

1988 ◽  
Vol 68 (1) ◽  
pp. 73-79 ◽  
Author(s):  
Raymond Sawaya ◽  
Robert Highsmith

✓ Fresh human brain-tumor samples were assayed for their plasminogen activator (PA) content. Specific molecular weight patterns were identified for each of five common brain tumors and for normal brain, suggesting a cell-specific origin of the various PA forms. Malignant tumors contained higher PA activity and a larger number of molecular weight patterns than benign tumors, with the exception of acoustic neurinomas. Irradiated tumors contained lower PA activity than nonirradiated tumors. Finally, a slight but definite correlation between brain edema and PA activity was detected. The future role of brain-tumor PA's for diagnostic and therapeutic purposes is discussed.


PLoS ONE ◽  
2011 ◽  
Vol 6 (11) ◽  
pp. e27442 ◽  
Author(s):  
Ana Gonzalez-Segura ◽  
Jose Manuel Morales ◽  
Jose Manuel Gonzalez-Darder ◽  
Ramon Cardona-Marsal ◽  
Concepcion Lopez-Gines ◽  
...  

1994 ◽  
Vol 81 (1) ◽  
pp. 69-77 ◽  
Author(s):  
Takao Nakagawa ◽  
Toshihiko Kubota ◽  
Masanori Kabuto ◽  
Kazufumi Sato ◽  
Hirokazu Kawano ◽  
...  

✓ The role of matrix metalloproteinases (MMP's) and their inhibitor, tissue inhibitor of metalloproteinases-1 (TIMP-1), in human brain tumor invasion was investigated. Gelatinolytic activity was assayed via gelatin zymography, and four MMP's (MMP-1, MMP-2, MMP-3, and MMP-9) and TIMP-1 were immunolocalized in human brain tumors and in normal brain tissues using monoclonal antibodies. The tissue was surgically removed from 44 patients: glioblastoma (five cases), anaplastic astrocytoma (six cases), astrocytoma (four cases), metastatic tumor (six cases), neurinoma (10 cases), meningioma (10 cases), and normal brain tissue (three cases). Glioblastomas, anaplastic astrocytomas, and metastatic tumors showed high gelatinolytic activity and positive immunostaining for MMP's; TIMP-1 was also expressed in these tumors, but some tumor cells were negative for the antibody. Astrocytomas had low gelatinolytic activity and the tumor cells showed no immunoreactivity for MMP's and TIMP-1. Although neurinomas and meningiomas had only moderate proteinase activity and exhibited positive immunoreactivity for MMP-9, intense expression of TIMP-1 was simultaneously observed in these tumor cells. These findings suggest that MMP's play an important role in human brain tumor invasion, probably due to an imbalance between the production of MMP's and TIMP-1 by the tumor cells.


2016 ◽  
Vol 127 (3) ◽  
pp. 473-482 ◽  
Author(s):  
Sven R. Kantelhardt ◽  
Darius Kalasauskas ◽  
Karsten König ◽  
Ella Kim ◽  
Martin Weinigel ◽  
...  

2012 ◽  
Vol 53 ◽  
pp. S254
Author(s):  
H. Jaksch-Bogensperger ◽  
T. Landrichinger ◽  
S. Weis ◽  
P. Eckl ◽  
C Hauser-Kronberger ◽  
...  

2009 ◽  
Vol 151 (5) ◽  
pp. 507-517 ◽  
Author(s):  
H. J. Böhringer ◽  
E. Lankenau ◽  
F. Stellmacher ◽  
E. Reusche ◽  
G. Hüttmann ◽  
...  

1978 ◽  
Vol 48 (2) ◽  
pp. 164-168 ◽  
Author(s):  
Kenneth J. Murray ◽  
Neil E. Kay ◽  
Steven D. Douglas

✓ Cyst fluids from 12 human brain tumors were studied for their blood-group content and compared to autologous saliva, serum, and cerebrospinal fluid (CSF). Lewisa substance, which is a fucolipid, was present in four of 12 cysts studied. Lewisb, which differs from Lewisa by a single fucose, was found in eight of 12 sera and/or saliva and in one CSF specimen; Lewisb substance, however, was not detected in any corresponding cyst fluids. Isohemagglutinins, blood-group antibodies anti-A and/or anti-B, were present in nine of nine cyst fluids studied, were of lower titers as compared to autologous serum, and occurred as either IgG or IgM immunoglobulins. The results further delineate the biochemical requirements necessary for molecular penetration into human brain-tumor cysts.


1989 ◽  
Vol 70 (4) ◽  
pp. 573-577 ◽  
Author(s):  
S. Clifford Schold ◽  
Thomas P. Brent ◽  
Eric von Hofe ◽  
Henry S. Friedman ◽  
Sankar Mitra ◽  
...  

✓ The level of O6-alkylguanine-deoxyribonucleic acid (DNA) alkyltransferase (AT) was determined in 15 human brain-tumor xenografts in athymic mice. This enzyme is a primary intracellular repair mechanism for lesions produced at the O6 position of guanine by a wide range of alkylating agents, including nitrosoureas and procarbazine. Its activity ranged from undetectable in five tumor lines to 2338 fmol/mg protein in N-1941, a human glioblastoma xenograft. The sensitivity of 10 of these xenografts to procarbazine was determined and it was found that four of the five tumor lines with AT levels of more than 100 fmol/mg protein had growth delays after procarbazine treatment of less than 20 days, whereas all five lines with undetectable AT levels had growth delays of over 30 days. The primary cytotoxic DNA adduct produced by procarbazine (namely, O6-methylguanine) was found to be significantly higher in two sensitive lines with low AT levels than in a highly resistant line with a high AT level. These data suggest that the AT levels of individual brain tumors can be used as predictive indicators of their susceptibility to drugs that exert their antineoplastic effect primarily by O6-alkylation of guanine in nuclear DNA.


Author(s):  
Duane R. Smith ◽  
Subhash Chandra ◽  
Jeffrey A. Coderre ◽  
Darrel D. Joel ◽  
Daniel N. Slatkin ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document